

ASX Announcement
21 November 2024 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Results of Annual general Meeting

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or 'the Company') hereby provides the results of its annual general meeting of shareholders held on 21 November 2024.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act is attached.

Resolutions 1 and 2 were passed on a poll. Resolution 3 was withdrawn at the meeting and not put to the meeting.

Details of resolutions, the proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached results summary.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Optiscan Imaging Limited
Annual General Meeting
Thursday, 21 November 2024
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	286,552,104 63.76%	155,437,760 34.59%	7,391,079 1.65%	265,811	338,276,482 99.90%	327,764 0.10%	155,375,807	Carried
2 Re-election of Director - Ron Song	Ordinary	454,824,609 98.38%	124,009 0.03%	7,391,079 1.59%	73,440	506,548,987 99.98%	124,009 0.02%	73,440	Carried
3 Approval of 7.1A Mandate	Special	Resolution was withdrawn							Not applicable

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Resolution(s) proposed but not put to the meeting

Resolution	Reason for not putting the resolution to the meeting
3 Approval of 7.1A Mandate	Resolution was withdrawn